Literature DB >> 628880

Control of argininosuccinate synthetase by arginine in human lymphoblasts.

J D Irr, L B Jacoby.   

Abstract

Human lymphoblasts in long-term culture have the enzyme activities necessary to convert citrulline to arginine: argininosuccinate synthetase and argininosuccinate lyase. Upon transfer from arginine-supplemented to citrulline-supplemented medium, lymphoblasts exhibit a lag period before resuming exponential growth. During this lag the specific activity of argininosuccinate synthetase increases an average of 60-fold. Argininosuccinate lyase activity remains unchanged. If normal lymphoblasts are starved in arginine-deficient medium without citrulline or if argininosuccinate lyase--deficient lymphoblasts are transferred to citrulline-containing medium, argininosuccinate synthetase activity increases linearly for several days and reaches even higher levels. Cycloheximide blocks the increase in enzyme activity. Cells grown in citrulline medium and pulse labeled with 35S-methionine incorporate more 35S-methionine into argininosuccinate synthetase protein than cells grown in arginine; the rate of disappearance of radioactively labeled enzyme is the same in citrulline- and arginine-grown cells. Arginine or a closely related metabolite thus appears to repress the synthesis of argininosuccinate synthetase of human lymphoblasts in culture.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 628880     DOI: 10.1007/bf01546496

Source DB:  PubMed          Journal:  Somatic Cell Genet        ISSN: 0098-0366


  10 in total

1.  Structure of the 5' end region of the human argininosuccinate synthetase gene.

Authors:  Y Jinno; H Nomiyama; S Matuo; K Shimada; I Matsuda; T Saheki
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

Review 2.  Transcriptional regulation of genes for ornithine cycle enzymes.

Authors:  M Takiguchi; M Mori
Journal:  Biochem J       Date:  1995-12-15       Impact factor: 3.857

3.  Molecular structure of the human argininosuccinate synthetase gene: occurrence of alternative mRNA splicing.

Authors:  S O Freytag; A L Beaudet; H G Bock; W E O'Brien
Journal:  Mol Cell Biol       Date:  1984-10       Impact factor: 4.272

4.  Isolation of a polymorphic DNA segment unique to human chromosome 7 by molecular cloning of hybrid cell DNA.

Authors:  P Humphries; D Barton; A M McKay; M M Humphries; B Carritt
Journal:  Mol Gen Genet       Date:  1983

5.  Argininosuccinate synthetase of bovine liver: chemical and physical properties.

Authors:  S Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

6.  Human argininosuccinate synthetase minigenes are subject to arginine-mediated repression but not to trans induction.

Authors:  F M Boyce; G M Anderson; C D Rusk; S O Freytag
Journal:  Mol Cell Biol       Date:  1986-04       Impact factor: 4.272

7.  Arginine-mediated regulation of an argininosuccinate synthetase minigene in normal and canavanine-resistant human cells.

Authors:  M J Jackson; W E O'Brien; A L Beaudet
Journal:  Mol Cell Biol       Date:  1986-06       Impact factor: 4.272

8.  Regulation of expression of genes for enzymes of the mammalian urea cycle in permanent cell-culture lines of hepatic and non-hepatic origin.

Authors:  D F Haggerty; E B Spector; M Lynch; R Kern; L B Frank; S D Cederbaum
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

9.  Expression of the human argininosuccinate synthetase gene in hamster transferents.

Authors:  L D Hudson; R W Erbe; L B Jacoby
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

10.  Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression.

Authors:  Anke Werner; Miriam Koschke; Nadine Leuchtner; Claudia Luckner-Minden; Alice Habermeier; Johanna Rupp; Christin Heinrich; Roland Conradi; Ellen I Closs; Markus Munder
Journal:  Front Immunol       Date:  2017-07-24       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.